Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma

Bladder cancer is considered as one of the main drivers of cancer related mortality in adult men. Data from Global Cancer Statistics 2018 (GLOBOCAN) showed that the bladder cancer was included among the Top 10 cancer incidence in worldwide. Meanwhile, metformin, an antidiabetic agent, is believed to...

Full description

Saved in:
Bibliographic Details
Main Authors: Anny Setijo Rahaju, Anny, Arifa Mustika, Arifa, Priangga Adi Wiratama, Priangga, Lukman Hakim, Lukman, Doddy M. Soebadi, -
Format: Article PeerReviewed
Language:English
English
English
English
Published: A and V Publication 2023
Subjects:
Online Access:https://repository.unair.ac.id/128128/1/Artikel%20Tambahan%205.pdf
https://repository.unair.ac.id/128128/2/Karil%205.pdf
https://repository.unair.ac.id/128128/3/Turnitin%20Tambahan%205.pdf
https://repository.unair.ac.id/128128/8/Etik%20Antitumor.pdf
https://repository.unair.ac.id/128128/
https://rjptonline.org/AbstractView.aspx?PID=2023-16-3-50
https://doi.org/10.52711/0974-360X.2023.00214
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universitas Airlangga
Language: English
English
English
English
id id-langga.128128
record_format dspace
spelling id-langga.1281282024-01-08T00:34:33Z https://repository.unair.ac.id/128128/ Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma Anny Setijo Rahaju, Anny Arifa Mustika, Arifa Priangga Adi Wiratama, Priangga Lukman Hakim, Lukman Doddy M. Soebadi, - R Medicine Bladder cancer is considered as one of the main drivers of cancer related mortality in adult men. Data from Global Cancer Statistics 2018 (GLOBOCAN) showed that the bladder cancer was included among the Top 10 cancer incidence in worldwide. Meanwhile, metformin, an antidiabetic agent, is believed to be able to impede the varying cancer cells expansion. Many examinations had displayed that metformin interferes via the AMPK/mTOR axis pathway, thereby suppressing tumor growth. AMPK activation can also increase stromal cell survival through p53 activation. Metformin also disrupts the cell cycle by decreasing the cyclin D1 protein in cancer cells. The human cell line 5637 was treated with metformin 15 mM, examined for cyclin D1 and p53 by immunohistochemical staining and assessed for the viability of cancer cells. The Statistic test was utilized to make a comparison of tumor viabilities and other variables. No significant differences were found in the expression of wild type p53 and cyclin D1 but significant differences were observed in the viability between the control and metformin groups. We have proven in our study that the anti-tumor effect of metformin in reducing the viability of urothelial carcinoma tumor cells not only through p53 and cyclin D1. A and V Publication 2023 Article PeerReviewed text en https://repository.unair.ac.id/128128/1/Artikel%20Tambahan%205.pdf text en https://repository.unair.ac.id/128128/2/Karil%205.pdf text en https://repository.unair.ac.id/128128/3/Turnitin%20Tambahan%205.pdf text en https://repository.unair.ac.id/128128/8/Etik%20Antitumor.pdf Anny Setijo Rahaju, Anny and Arifa Mustika, Arifa and Priangga Adi Wiratama, Priangga and Lukman Hakim, Lukman and Doddy M. Soebadi, - (2023) Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma. Research Journal of Pharmacy and Technology, 16 (3). pp. 1303-1308. ISSN 0974-3618 E-ISSN: 0974-360X https://rjptonline.org/AbstractView.aspx?PID=2023-16-3-50 https://doi.org/10.52711/0974-360X.2023.00214
institution Universitas Airlangga
building Universitas Airlangga Library
continent Asia
country Indonesia
Indonesia
content_provider Universitas Airlangga Library
collection UNAIR Repository
language English
English
English
English
topic R Medicine
spellingShingle R Medicine
Anny Setijo Rahaju, Anny
Arifa Mustika, Arifa
Priangga Adi Wiratama, Priangga
Lukman Hakim, Lukman
Doddy M. Soebadi, -
Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma
description Bladder cancer is considered as one of the main drivers of cancer related mortality in adult men. Data from Global Cancer Statistics 2018 (GLOBOCAN) showed that the bladder cancer was included among the Top 10 cancer incidence in worldwide. Meanwhile, metformin, an antidiabetic agent, is believed to be able to impede the varying cancer cells expansion. Many examinations had displayed that metformin interferes via the AMPK/mTOR axis pathway, thereby suppressing tumor growth. AMPK activation can also increase stromal cell survival through p53 activation. Metformin also disrupts the cell cycle by decreasing the cyclin D1 protein in cancer cells. The human cell line 5637 was treated with metformin 15 mM, examined for cyclin D1 and p53 by immunohistochemical staining and assessed for the viability of cancer cells. The Statistic test was utilized to make a comparison of tumor viabilities and other variables. No significant differences were found in the expression of wild type p53 and cyclin D1 but significant differences were observed in the viability between the control and metformin groups. We have proven in our study that the anti-tumor effect of metformin in reducing the viability of urothelial carcinoma tumor cells not only through p53 and cyclin D1.
format Article
PeerReviewed
author Anny Setijo Rahaju, Anny
Arifa Mustika, Arifa
Priangga Adi Wiratama, Priangga
Lukman Hakim, Lukman
Doddy M. Soebadi, -
author_facet Anny Setijo Rahaju, Anny
Arifa Mustika, Arifa
Priangga Adi Wiratama, Priangga
Lukman Hakim, Lukman
Doddy M. Soebadi, -
author_sort Anny Setijo Rahaju, Anny
title Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma
title_short Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma
title_full Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma
title_fullStr Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma
title_full_unstemmed Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma
title_sort antitumor activity of metformin through p53 and cyclin d1 in the urothelial cell carcinoma
publisher A and V Publication
publishDate 2023
url https://repository.unair.ac.id/128128/1/Artikel%20Tambahan%205.pdf
https://repository.unair.ac.id/128128/2/Karil%205.pdf
https://repository.unair.ac.id/128128/3/Turnitin%20Tambahan%205.pdf
https://repository.unair.ac.id/128128/8/Etik%20Antitumor.pdf
https://repository.unair.ac.id/128128/
https://rjptonline.org/AbstractView.aspx?PID=2023-16-3-50
https://doi.org/10.52711/0974-360X.2023.00214
_version_ 1787591124965130240